Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A 2.5-year-old boy was diagnosed with myeloproliferative disorder and eosinophilia associated with lymphoblastic lymphoma both bearing the CCDC88C-PDGFRB fusion.
|
30726835 |
2019 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The platelet-derived growth factor receptor β (PDGFRB) gene translocations lead to a spectrum of chronic myeloid neoplasms, frequently associated with eosinophilia.
|
31085913 |
2019 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular studies were negative for Fip1-like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) translocation and PDGFRB and FGFR mutations, indicating nonclonal eosinophilia.
|
29714651 |
2018 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
|
28725989 |
2017 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although patients with PDGFRB rearrangement mostly present with myeloproliferative neoplasm and eosinophilia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) have also been reported in this population.
|
28000100 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation includes assessment for reactive causes of eosinophilia (vasculitis such as eosinophilic granulomatosis and polyangiitis or Churg-Strauss, parasitic infection, autoimmune disease, immunoglobulinG4-related disease, medications and other causes), genetic lesions characteristic of clonal myeloid disorders (platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and flow cytometry and molecular studies for the aberrant T cells characteristic of lymphocyte-variant HES .
|
29173361 |
2017 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Diverse rearrangements involving the PDGFRB gene have been identified in myeloid and lymphoid neoplasms with eosinophilia, but rearrangement of the nuclear mitotic apparatus protein 1 (NUMA1) gene has previously been reported in a human malignancy in only one instance, a NUMA1-RARA fusion caused by a t(11;17) translocation in a patient with acute promyelocytic leukemia.
|
28449810 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
|
24772479 |
2014 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms.
|
24687085 |
2014 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we developed version 2.0 of a genomically based systematic kinase fusion screen and used it to detect a novel imatinib-sensitive C6orf204-PDGFRB fusion in a patient with precursor T lymphoblastic lymphoma (T-ALL) and an associated myeloproliferative neoplasm with eosinophilia.
|
21938754 |
2012 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Most of the patients showed moderate anaemia (median Hb was 10.0 gr/dL; range from 7.5 to 13 g/dL), leukocytosis (median white blood cells was 21.7 × 10(9) /L with a range from 4 to 43 × 10(9) /L) and eosinophilia (median circulating eosinophils was 2.4 × 10(9) /L with a range of 1.1-5.7 × 10(9) /L) with a median of bone marrow infiltration cells displaying PDGFRB rearrangement of 55% (range, 37-85%).
|
22587685 |
2012 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital.
|
22488677 |
2012 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B.
|
20972453 |
2011 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The fusion of TEL with platelet-derived growth factor receptor (PDGFR) beta (TPbeta) is found in a subset of patients with atypical myeloid neoplasms associated with eosinophilia and is the archetype of a larger group of hybrid receptors that are produced by rearrangements of PDGFR genes.
|
20164181 |
2010 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, significant overexpression of PDGFRB was found in a patient with an eosinophilia-associated myeloproliferative neoplasm with uninformative cytogenetics and an excellent response to imatinib.
|
20107158 |
2010 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hematological malignancies with eosinophilia are often associated with fusions in PDGFRA, PDGFRB, or FGFR1 genes.
|
20615084 |
2010 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloid neoplasm associated with eosinophilia and abnormality of PDGFRβ was then diagnosed (Tefferi A, Vardiman JW, Leukemia, 22, 2008, 14).
|
21054467 |
2010 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasms are now classified into five categories: acute myeloid leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN, and myeloid and/or lymphoid malignancies associated with eosinophilia and PDGFR or FGFR1 rearrangements.
|
19806146 |
2009 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
|
19006078 |
2009 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BCR-ABL1 is associated with chronic myelogenous leukaemia (CML) and mutant PDGFR with an MPN phenotype characterized by eosinophilia and in addition, in case of FIP1L1-PDGFRA, bone marrow mastocytosis.
|
19175693 |
2009 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HES and CEL-NOC are considered distinct from molecularly defined eosinophilic disorders, such as those associated with activating mutations of PDGFR (PDGFRA and PDGFRB) and fibroblast growth factor receptor-1.
|
20425445 |
2008 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization (FISH) and reverse-transcription polymerase chain reaction (RT-PCR) detected the ETV6-PDGFRB fusion in a patient with chronic myelomonocytic leukemia characterized by bone marrow and peripheral blood eosinophilia and a four-way t(1;12;5;12)(p36;p13;q33;q24) on bone marrow cells.
|
17574967 |
2007 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rearrangements involving PDGFRA and PDGFRB in eosinophilic chronic myeloproliferative disorders, and of fibroblast growth factor receptor 1 (FGFR1) in the 8p11 stem cell myeloproliferative syndrome constitute additional examples of specific genetic alterations linked to clonal eosinophilia.
|
16781488 |
2006 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Similarly, the drug has now been shown to display equally impressive therapeutic activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene.
|
15166033 |
2004 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We describe the fusion of TP53BP1 to PDGFRB in a patient with a chronic myeloid leukemia-like disorder associated with eosinophilia and a t(5;15)(q33;q22).
|
15492236 |
2004 |